Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Hoth Therapeutics, Inc. HOTH
$1.58
-$0.02 (-1.24%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
5217334.00000000
-
week52high
17.50
-
week52low
1.52
-
Revenue
0
-
P/E TTM
0
-
Beta
0.11864400
-
EPS
-9.34000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 ноя 2021 г. в 10:59
Описание компании
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| EF Hutton | Buy | Buy | 23 авг 2022 г. |
| EF Hutton | Buy | Buy | 31 мар 2022 г. |
| Benchmark | Speculative Buy | 15 окт 2019 г. | |
| Laidlaw & Co. | Buy | 20 мая 2019 г. | |
| EF Hutton | Buy | Buy | 30 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Pavell Jeff | A | 5075 | 5075 | 13 дек 2022 г. |
| Knie Robb | A | 828259 | 10000 | 19 сент 2022 г. |
| Knie Robb | A | 818259 | 10000 | 16 сент 2022 г. |
| Linsley Wayne | A | 40000 | 40000 | 16 мар 2022 г. |
| Springer Graig | A | 250000 | 250000 | 16 мар 2022 г. |
| Springer Graig | A | 40000 | 40000 | 16 мар 2022 г. |
| Sarnoff David | A | 40000 | 40000 | 16 мар 2022 г. |
| Johns Stefanie | A | 250000 | 250000 | 16 мар 2022 г. |
| Knie Robb | A | 500000 | 500000 | 16 мар 2022 г. |
| Knie Robb | A | 225000 | 225000 | 29 янв 2021 г. |
Новостная лента
Are Penny Stocks Worth the Risk? 3 Reasons Why They Could Be
PennyStocks
23 февр 2023 г. в 06:00
Are penny stocks worth investing in? The post Are Penny Stocks Worth the Risk?
Why Hoth Therapeutics Shares Are Nosediving - Hoth Therapeutics (NASDAQ:HOTH)
Benzinga
30 дек 2022 г. в 10:59
Hoth Therapeutics Inc HOTH shares are trading lower by 21.22% to $8.44 Friday morning after the company announced a $10 million private placement priced at-the-market under Nasdaq rules.
Why Is Hoth Therapeutics (HOTH) Stock Up 24% Today?
InvestorPlace
31 окт 2022 г. в 13:12
Hoth Therapeutics (NASDAQ: HOTH ) stock is rising higher on Monday positive results from a Phase 1 clinical trial of BioLexa. BioLexa is a treatment in development at Hoth Therapeutics for mild-to-moderate atopic dermatitis in adult patients.
Hoth Therapeutics Announces Pipeline Presentation at the 2022 Sidoti Investor Conference
PRNewsWire
12 авг 2022 г. в 13:48
NEW YORK , Aug. 12, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced today announced the company will be presenting at the Sidoti Investor Conference taking place on August 17-18, 2022. To learn more about the Sidoti Investor Conference or register to attend visit https://www.sidoti.com/events About Hoth Therapeutics, Inc. Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to develop innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life.
Hoth Therapeutics Shares Surge On Encouraging Preclinical Data From Alzheimer's Program
Benzinga
12 июл 2022 г. в 14:37
Hoth Therapeutics Inc (NASDAQ: HOTH) has announced proof-of-concept data generated using cognitive and behavioral assessments in an Alzheimer's disease mouse model. HT-ALZ is therapeutic in development under the 505(b)(2) regulatory pathway for dementia related to Alzheimer'.